Aldeyra Raises Additional Capital To Fund Dry Eye Treatment

ALDX recently raised nearly $27MM to fund its dry eye treatment. Fresh capital gives ALDX flexibility to partner with big pharma for drug development or go it alone. The dry eye market offers huge upside for a new entrant. ALDX is a buy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.